Maze Therapeutics, Inc.
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule precision medicines for renal, cardiovascular and related metabolic diseases, including obesity. It uses its Compass platform to link human genetic variants to disease biology and advance programs such as MZE829 and MZE782, while also monetizing select discovery assets through licensing and collaboration deals.
Fiscal year 2025 · change from previous year
Development 2024–2025
Business
Share of revenueLead small-molecule drug programs being tested in humans for renal and CVRM diseases.
Earlier-stage programs generated from the Compass platform and internal research.
Human genetics and variant functionalization tools used to identify and validate targets.
Upfront payments, milestones and royalties from out-licensing selected programs.
Customers
Maze does not sell approved products today; its near-term counterparties are pharmaceutical partners and, eventually, physicians, patients and payors if its candidates reach commercialization. The company’s current economic value is driven by licensing partners and clinical development progress, while future demand would come from patients with CKD, APOL1-mediated kidney disease and related metabolic conditions.
Biopharma companies that pay upfronts, milestones or royalties for selected targets and programs.
Potential end users of MZE829, MZE782 and future renal therapies if approved.
Nephrologists and other clinicians who would adopt the therapy based on efficacy, safety and convenience.
Insurers and reimbursement bodies that determine access and pricing for approved medicines.
Groups that can support awareness, trial enrollment and eventual market acceptance.
Strategy
Maze’s strategy is to use human genetics and its Compass platform to identify disease-driving pathways, then advance precision medicines into the clinic for renal and CVRM diseases. It is prioritizing MZE829 and MZE782, broadening the pipeline, and using partnerships or licensing to help fund development while preserving optionality around commercialization.
Clinical proof-of-concept is the main value driver for a pre-commercial biotech.
A deeper pipeline reduces single-asset risk and increases partnering optionality.
The company expects continued losses and needs funding to reach later milestones.
Geography
Q1/2026Maze is headquartered in the United States and its development, regulatory and financing activities are primarily U.S.-based. The company has disclosed potential foreign regulatory interaction and collaboration activity, but no country-level revenue concentration is provided in the excerpts, reflecting its pre-commercial stage and reliance on licensing rather than product sales.
Risks
Maze faces the classic risks of a clinical-stage biotech: clinical failure, safety issues, regulatory delays and the need for substantial additional capital before any product revenue. Its focus on CKD and genetically defined populations may improve differentiation, but it also creates dependence on market acceptance, reimbursement and successful execution of complex trials.
- Clinical development failureImpact: HighLikelihood: Medium
MZE829, MZE782 and other programs may not demonstrate sufficient safety or efficacy.
Exposure: Lead pipeline value and future commercialization
- Funding shortfall and dilutionImpact: HighLikelihood: Medium
The company expects to require substantial additional capital before meaningful revenue.
Exposure: Operating runway and pipeline continuity
- Regulatory and safety setbacksImpact: HighLikelihood: Medium
FDA approval, REMS requirements or adverse events could delay or block development.
Exposure: Clinical timelines and approval probability
- Commercial market acceptanceImpact: MediumLikelihood: Low
Even approved therapies may not gain physician, patient or payor adoption.
Exposure: Future product revenue and profitability
- Competitive pressure in CKDImpact: MediumLikelihood: Low
Established RAAS, SGLT2 and GLP-1 therapies and new APOL1 entrants compete for the same patients.
Exposure: Pricing power and market share
- Partner and spin-out governance riskImpact: MediumLikelihood: Low
Joint ventures and spin-outs can create conflicts, execution issues and reputational exposure.
Exposure: Non-core collaborations and target monetization
Accounting
Judgemental itemsUpfront payments from Shionogi, Trace and Neurocrine create non-recurring revenue timing effects.
Impact: Can cause large period-to-period swings unrelated to core operating performance
Clinical trial, manufacturing and outside-service costs depend on program stage and vendor estimates.
Impact: Directly affects operating loss and comparability across quarters
The company expects to need additional capital before commercial revenue begins.
Impact: Affects runway disclosure and financing risk assessment
Headcount growth and public listing increase non-cash and overhead expenses.
Impact: Influences reported losses and adjusted operating trends
Similar listed companies
Publicly listed companies with a comparable business focus.
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
MapLight Therapeutics, Inc.
MPLT · Pharmaceutical Preparations
Voyager Therapeutics, Inc.
VYGR · Biological Products, (No Diagnostic Substances)
Compass Therapeutics, Inc.
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
Tango Therapeutics, Inc.
TNGX · Pharmaceutical Preparations
Last updated: 24/09/2026